![]() |
Name |
dehydropestalotin
|
Molecular Formula | C11H16O4 | |
IUPAC Name* |
6-(1-hydroxypentyl)-4-methoxypyran-2-one
|
|
SMILES |
CCCCC(O)c1cc(OC)cc(=O)o1
|
|
InChI |
InChI=1S/C11H16O4/c1-3-4-5-9(12)10-6-8(14-2)7-11(13)15-10/h6-7,9,12H,3-5H2,1-2H3
|
|
InChIKey |
FWFKXWDSIIPMJT-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 212.24 | ALogp: | 1.9 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 59.7 | Aromatic Rings: | 1 |
Heavy Atoms: | 15 | QED Weighted: | 0.814 |
Caco-2 Permeability: | -4.791 | MDCK Permeability: | 0.00003680 |
Pgp-inhibitor: | 0.047 | Pgp-substrate: | 0.73 |
Human Intestinal Absorption (HIA): | 0.029 | 20% Bioavailability (F20%): | 0.368 |
30% Bioavailability (F30%): | 0.99 |
Blood-Brain-Barrier Penetration (BBB): | 0.541 | Plasma Protein Binding (PPB): | 82.26% |
Volume Distribution (VD): | 0.741 | Fu: | 24.19% |
CYP1A2-inhibitor: | 0.583 | CYP1A2-substrate: | 0.952 |
CYP2C19-inhibitor: | 0.252 | CYP2C19-substrate: | 0.702 |
CYP2C9-inhibitor: | 0.1 | CYP2C9-substrate: | 0.881 |
CYP2D6-inhibitor: | 0.019 | CYP2D6-substrate: | 0.876 |
CYP3A4-inhibitor: | 0.022 | CYP3A4-substrate: | 0.288 |
Clearance (CL): | 10.329 | Half-life (T1/2): | 0.735 |
hERG Blockers: | 0.049 | Human Hepatotoxicity (H-HT): | 0.272 |
Drug-inuced Liver Injury (DILI): | 0.193 | AMES Toxicity: | 0.03 |
Rat Oral Acute Toxicity: | 0.099 | Maximum Recommended Daily Dose: | 0.292 |
Skin Sensitization: | 0.365 | Carcinogencity: | 0.074 |
Eye Corrosion: | 0.248 | Eye Irritation: | 0.857 |
Respiratory Toxicity: | 0.119 |